We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Siena Expands MetaCore License From GeneGo

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GeneGo, Inc. has announced that Siena Biotech has expanded the number of MetaCore licenses obtained from GeneGo.

MetaCore's technology platform's capacity to integrate multiple data types including proteomics and chemogenomics data was valued by Siena Biotech together with the quality of content in neurological diseases.

"We appreciate MetaCore's flexibility and GeneGo's ability to quickly implement customer feedback," said Dr. Georg C. Terstappen, Vice President Discovery Research, of the Italian Company.

"GeneGo and Siena Biotech in their respective fields are leading the way in pathway proteomics: we expect advantages for both companies form this collaboration."

"We are very pleased to expand our relationship with Siena Biotech," said Julie Bryant, Vice President of Business Development at GeneGo.

"We are seeing more of our customers expanding the scope of data types analyzed in MetaCore in their R&D efforts."

"MetaCore is well equipped for this with its capacity to concurrently visualize, score and process gene expression, proteomic, metabolomic and compound data."